Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Mascaretti, Federica; Haider, Salman; Amoroso, Chiara; Caprioli, Flavio; Ramai, Daryl; Ghidini, Michele

doi:10.1007/s12029-024-01021-x

Cited by 3 publications

(2 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intake of probiotics and prebiotics is being researched to enhance therapeutic results and lessen side effects related to anticancer medication. [55] The EVs and CFS of the L. crispatus strain RIGLD-1 are possible therapeutic agents to combat inflammation caused by H. pylori. [56] One possible nanovaccine to be used in an oral vaccination against H. pylori infection is alginate/pCI-neo-UreH.…”

Section: Current Treatment Options Studies Referencesmentioning

confidence: 99%

“…Interventions such as the use of probiotics, prebiotics, or antibiotics can alter the gut microbiota. GC is associated with dysbiosis and immunological dysregulation caused by alterations in the normal gut microbiota [ 55 ]. Traditional antibiotic therapy in conjunction with probiotics and postbiotics is currently receiving much attention for the treatment of H. pylori infection.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update

Burz,

Pop,

Silaghi

et al. 2024

Cancers

View full text Add to dashboard Cite

Numerous studies have been performed on Helicobacter pylori infection because of the high death rate linked to this illness and gastric cancer. An update on the key developments in recent years in the investigation of Helicobacter pylori and gastric cancer is the goal of this review. Using the search term “Helicobacter pylori, gastric cancer”, the PubMed database was searched. Only papers published in 2024 fulfilled the inclusion criteria. Because case report papers were not part of our investigation, they satisfied the exclusion criteria. Most of the research on the variable genes of Helicobacter pylori is guided by genetics to determine potential treatments. Studies on clinical treatments for the eradication of H. pylori with promising therapeutic options are needed. We found the fewest studies related to the immunopathology of H. pylori infection, which is still unknown. In conclusion, priority should be given to this kind of research.

show abstract

Section: Current Treatment Options Studies Referencesmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update

Burz,

Pop,

Silaghi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Letter to the Editor: Comment on: Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Kountouras,

Kazakos,

Polyzos

et al. 2024

J Gastrointest Canc

View full text Add to dashboard Cite

Immunotherapy in Gastro-Esophageal Cancers

Sezgin,

Kara

2024

Immunotherapy in Human Cancers

View full text Add to dashboard Cite

Cancers of the gastro-oesophageal system represent the fourth most common cancer type, following lung and breast cancers. Mortality rates remain high due to late diagnosis. In the context of gastrointestinal malignancies, the tumour microenvironment and immune system play a pivotal role in cancer progression and treatment response. The role of immunotherapy in the treatment of gastroesophageal cancers has become increasingly significant in recent years. Immunotherapy, which was previously employed solely in the context of metastatic gastric cancer, has recently been established as a standard treatment modality in the adjuvant management of oesophageal cancer that has undergone neoadjuvant therapy and remains following surgical resection. Furthermore, studies are currently underway to assess the efficacy of combining immunotherapy with standard chemotherapy regimens in the neoadjuvant treatment of gastric cancer. Preclinical and clinical evidence has demonstrated the effectiveness of anti-PD1 and anti-PDL1 agents in gastroesophageal cancers, and these agents are now included in current guidelines. In addition to these agents, studies are ongoing to evaluate the potential of CTLA-4 inhibitors and vaccines in this setting.

show abstract

Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Cited by 3 publications

References 179 publications

Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update

Helicobacter pylori Infection in Patients with Gastric Cancer: A 2024 Update

Letter to the Editor: Comment on: Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Immunotherapy in Gastro-Esophageal Cancers

Contact Info

Product

Resources

About